If you have been reading about ipamorelin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-03. Numbers and descriptions here follow the published literature rather than marketing material.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Reported for the free peptide |
| Molecular mass | 711.85 Da | Monoisotopic value |
| Residue motif | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Non-natural residues at positions one and three |
| Primary target | GHSR-1a | Ghrelin receptor, G protein coupled |
| Reported plasma half-life | About two hours | Values vary with assay and subject group |
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
== Table of techniques == In the table below, ambient ionization techniques are classified in the categories "extraction" (a solid or liquid extraction processes dynamically followed by spray or chemical ionization), "plasma" (thermal or chemical desorption with chemical ionization), "two step" (desorption or ablation followed by ionization), "laser" (laser desorption or ablation followed by ionization), "acoustic" (acoustic desorption followed by ionization), multimode (involving two of the above modes), other (techniques that do not fit into the other categories).
=== Mods === Mod tools for the Source 2 engine and Steam Workshop support for Half-Life: Alyx were released on May 15, 2020. Valve announced plans to release a new Hammer level editor for Source 2, and planned to release a partial Source 2 software development kit for the updated features later, with the focus at launch on shipping and supporting Alyx. In March 2023, fans released the "NoVR" mod, which allows Alyx to be played without a VR headset. This also allows Alyx to run on less powerful devices, such as the Steam Deck. Reviewers found the mod removed immediacy and that mouse-and-keyboard controls could not replicate the dexterity of VR controllers.
Fibronectin type III domain-containing protein 5, the precursor of irisin, is a type I transmembrane glycoprotein that is encoded by the FNDC5 gene. Irisin is a cleaved version of FNDC5, named after the Greek messenger goddess Iris. Fibronectin domain-containing protein 5 is a membrane protein comprising a short cytoplasmic domain, a transmembrane segment, and an ectodomain consisting of a ~100 kDa fibronectin type III (FNIII) domain.
== Trends in the chart of nuclides == The trends in this section refer to the following chart, which shows Z increasing to the right and N increasing downward, a 90° clockwise rotation of the above landscape-orientation charts.
As a mucous connective tissue, it is rich in proteoglycans, and protects and insulates umbilical blood vessels. Wharton's jelly, when exposed to temperature changes, collapses structures within the umbilical cord and thus provides a physiological clamping of the cord, typically three minutes after birth.
Sources: en.wikipedia.org
=== Stroke prevention === Transcranial Doppler ultrasound (TCD) can detect children with sickle cell who have a high risk for stroke. The ultrasound test detects partially obstructed blood vessels by measuring blood flow into the brain, as blood flow velocity is inversely related to arterial diameter. Consequently, high blood flow velocity correlates with narrowed arteries. In children, preventive RBC transfusion therapy has been shown to reduce the risk of first stroke or silent stroke when transcranial Doppler ultrasonography shows abnormal cerebral blood flow. In those who have sustained a prior stroke event, it also reduces the risk of recurrent stroke and additional silent strokes.
== Epidemiology == Weissenbacher-Zweymüller syndrome affects males and females in the same numbers. About 30 cases have been reported in medical literature. The disorder can be underdiagnosed causing no true frequency in the population.
== History == Interchim was founded by Boch Jean (formerly chemical engineer at Rhone-Poulenc) and Boch Colette in 1970. Their initial activity started with distribution of fine chemicals, then chromatography and Biology. Production was developed as well, in each fields. Affiliate companies were created for production and commercial activities in France, UK (2003), USA (2007) and Instrumentation business (2010). Interchim has now major activity in fine chromatography, fine chemistry and bio-analysis. Leadership in analytical sciences is based on distribution from leading groups (Agilent, Perkin Elmer, Jackson Immunoresearch, Novus, Radleys...), collaborations and proprietary innovative products.
The International History Review. 30 (4): 709–740. doi:10.1080/07075332.2008.10416646. ISSN 1949-6540. JSTOR 40213728. S2CID 153677447. Panzac, Daniel (1995). Histoire économique et sociale de l'Empire ottoman et de la Turquie (1326-1960). Peeters Publishers. ISBN 90-6831-799-7. Pappé, Ilan (2006). The Ethnic Cleansing of Palestine. Oneworld. ISBN 978-1-85168-555-4. Reilly, James A. (2016). The Ottoman Cities of Lebanon: Historical Legacy and Identity in the Modern Middle East. London: I. B. Tauris. ISBN 978-1-78672-036-8. Salibi, Kamal S. (January 1961). "The Buḥturids of the Garb. Mediaeval Lords of Beirut and of Southern Lebanon". Arabica. 8 (1): 74–97. doi:10.1163/157005861X00043. JSTOR 4054971. Salibi, K. (1965). "Fakhr al-Dīn". In Lewis, B.; Pellat, Ch. & Schacht, J. (eds.). The Encyclopaedia of Islam, Second Edition. Volume II: C–G. Leiden: E. J. Brill. pp. 749–751. OCLC 495469475. Salibi, K. (February 1968). "The muqaddams of Bšarrī: Maronite chieftains of the Northern Lebanon 1382–1621". Arabica. 15 (1): 63–86. doi:10.1163/157005868X00280. ISSN 0570-5398. JSTOR 4056124. Salibi, K. (2005). A House of Many Mansions: The History of Lebanon Reconsidered. London: I.B. Tauris. ISBN 978-1-86064-912-7. Salibi, Kamal Suleiman (2005b). The Druze: Realities & Perceptions. University of Michigan Press. ISBN 978-1-904850-06-9. Schilcher, L. Schatkowski (1981). "The Hauran Conflicts of the 1860s: A Chapter in the Rural History of Modern Syria". International Journal of Middle East Studies. 13 (2): 159–179. doi:10.1017/S0020743800055276. JSTOR 162818. S2CID 162263141.
=== In Anthropology === An anthropological lens challenges the idea that drug use is a universal problem, instead suggesting that perceptions of substance use and addiction depend on social, historical, political and cultural context. Drug policy and public responses vary globally, with disparities between the United Kingdom, Australia, and the United States. In the UK, drug use has become framed on crime prevention and coercion of drug users, demonstrating that definitions of harm are culturally and politically bound, questioning who health policies benefit. The USA has focused on the criminalisation of drug use, framing drug users as “morally reprehensible” and “deviant criminals”, shaping drug use as an issue of crime and social order. Australia’s 1985 adoption of harm minimisation strategies highlights that policy can shift alongside historical circumstances. The HIV/AIDS epidemic prompted a focus on safe injecting, rather than eradicating drug use. Maher and Dixon’s ethnographic research revealed that “attempts to suppress or control” drug use can shape how it is carried out, demonstrating that drug policy can shape experiences of harm. These cases corroborate Singer’s idea that drug use must be understood in its context, which challenges the narrative that drug-related harm is solely the users’ responsibility.
Sources: en.wikipedia.org
Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.
Early animal and human studies reported growth hormone release at levels that produced small changes in cortisol, prolactin and adrenocorticotropic hormone. That contrast with older secretagogues gave rise to the selectivity label. The observation is consistent across several reports but rests on a limited number of small studies.
Plasma peptidases cleave the molecule into smaller fragments, and reported half-lives in human studies are on the order of a couple of hours. The identity and activity of individual breakdown products have not been fully mapped. Questions about tissue-level clearance remain open.
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.